{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-032425","form_type":"8-K","ticker":null,"cik":"0001358762","company_name":"REATA PHARMACEUTICALS INC","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.697586+00:00","generated_at":"2026-06-13T09:55:55.437422+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Reata Pharmaceuticals closes $50M Tranche B loan under $275M facility","bullets":["Closed $50 million Tranche B loan on July 10, 2023, under $275 million loan agreement.","Funding triggered by FDA approval of the company's prior approval submission.","Loan agreement initially entered on May 5, 2023, with BPCR Limited Partnership and BioPharma Credit."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-032425","json":"https://secwatch.observer/filing/0000950170-23-032425.json","markdown":"https://secwatch.observer/filing/0000950170-23-032425.md","text":"https://secwatch.observer/filing/0000950170-23-032425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1358762/000095017023032425/0000950170-23-032425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1358762/000095017023032425/reta-20230710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:55:55.437422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a69c3069c4cda6c3645ef19fde24bbc0414f771","claim":"REATA PHARMACEUTICALS INC incurred term loan of $50 million with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC.","evidence_excerpt":"On July 10, 2023, the Borrower closed the second Tranche (the Tranche B Loan) of $50 million under the Loan Agreement.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358762/000095017023032425/0000950170-23-032425-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$50 million"},{"label":"Counterparty","value":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"a3d1c5addc8ae1fd74fd579f16700fc78504b7e0","claim":"REATA PHARMACEUTICALS INC entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $275 million (effective 2023-05-05).","evidence_excerpt":"On May 5, 2023, we, as the Borrower, and certain of our direct and indirect subsidiaries party thereto from time to time, as the guarantors, entered into a loan agreement (the Loan Agreement) with BPCR Limited Partnership (as a Lender), BioPharma Credit Investments V (Master) LP (as a Lender), and BioPharma Credit PLC, as collateral agent for the Lenders, pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate amount of up to $275 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358762/000095017023032425/0000950170-23-032425-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC"},{"label":"Value","value":"up to $275 million"},{"label":"Effective","value":"2023-05-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}